MHRA Licenses Brensocatib for Non-Cystic Fibrosis Bronchiectasis
The MHRA has granted a marketing authorisation for brensocatib (Brinsupri), the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older. This marks a significant advancement in treatment options for NCFB patients in the UK.
Priority review
Guidance
Pharmaceuticals
MHRA Class 2 Medicines Recall: KidNaps Melatonin Oral Solution
The MHRA has issued a Class 2 medicines recall for all batches of KidNaps Melatonin 1mg in 1ml Oral Solution due to out-of-specification stability results. Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are conducting the recall at the wholesaler and pharmacy level.
Priority review
Notice
Pharmaceuticals